Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy

Go back to Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy
Stratcomm Media, Ltd. (NASDAQ: SMMT) Delayed: 17.59 +0.42 (2.45%)
Previous Close $17.17    52 Week High $19.75 
Open $17.36    52 Week Low $4.26 
Day High $17.62    P/E N/A 
Day Low $16.82    EPS $0.00 
Volume 5,754,954       

SAREPTA THERAP (NASDAQ: SRPT) Delayed: 17.85 -0.36 (1.98%)
Previous Close $18.21    52 Week High $63.73 
Open $18.25    52 Week Low $8.00 
Day High $18.53    P/E N/A 
Day Low $17.68    EPS $-5.69 
Volume 3,015,057       

AyreTrade, Inc. (AMEX: SUMM) Delayed: 0.06 --0 (-0%)
Previous Close $0.06    52 Week High $0.24 
Open $40.78    52 Week Low $0.02 
Day High $0.06    P/E N/A 
Day Low $0.06    EPS $0.00 
Volume 7,226,927